Cell:里程碑研究揭示肿瘤进化与前列腺癌严重性存在关联

2018-05-10 佚名 细胞

在一项新的研究中,来自加拿大前列腺癌基因组网络(Canadian Prostate Cancer Genome Network, CPC-GENE)分析了293例与临床结果数据相关联的局限性前列腺癌的全基因组序列。他们进一步利用机器学习(一种统计学技术)推断肿瘤的进化过程和评估它们的轨迹。他们发现那些已进化出多种类型的癌细胞或者亚克隆的肿瘤是最具侵袭性的。在这项研究中,55%的肿瘤具有这种遗传多样

在一项新的研究中,来自加拿大前列腺癌基因组网络(Canadian Prostate Cancer Genome Network, CPC-GENE)分析了293例与临床结果数据相关联的局限性前列腺癌的全基因组序列。他们进一步利用机器学习(一种统计学技术)推断肿瘤的进化过程和评估它们的轨迹。他们发现那些已进化出多种类型的癌细胞或者亚克隆的肿瘤是最具侵袭性的。在这项研究中,55%的肿瘤具有这种遗传多样性,而且在这些具有这种遗传多样性的肿瘤中,61%的肿瘤在接受标准治疗后经历癌症复发。相关研究结果发表在2018年5月3日的Cell期刊上,论文标题为“The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression”。

这些发现表明人们能够通过研究每例前列腺癌的进化方式来准确地评估它的侵袭性。这些信息能够被用来确定应给予每名患者何种类型的治疗和多少剂量的治疗(如果需要接受治疗的话)。

Paul Boutros博士说,“通过将时间与在诊断时我们对肿瘤所在位置的现有知识背景相结合,我们能够非常准确地鉴定出哪些前列腺肿瘤不需要治疗的男性患者,哪些可通过现有治疗方法治愈的男性患者以及哪些患有侵袭性前列腺瘤并且可能从新的治疗选择中获益的男性患者。”

Robert Bristow教授说,“作出治疗前列腺癌的临床决策可能是非常困难的。这些发现为改善我们确定每位患者的最佳治疗方案的能力铺平了道路,以便避免患者接受不必要的治疗或过度治疗和由此带来的相副作用。”

Quaid Morris副教授说,“肿瘤是由相关的癌细胞组成的一个细胞群体,通过利用机器学习研究它们的DNA,我们能够深入地认识它们是如何由正常的细胞进化而来的。在这篇论文中,我们证实肿瘤的过去进化史有助于预测它是否会进展为一种侵袭性的形式。”

这项研究的发现并不局限于对前列腺癌研究作出贡献。在研究过程中产生的测序数据如今可以在线免费让全球研究人员开展进一步分析,并且成为迄今为止最大的前列腺癌基因组学资源。

原始出处:

Espiritu SMG,et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell. 2018 May 3;173(4):1003-1013.e15.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059300, encodeId=e415205930097, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 03 18:54:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870623, encodeId=a8e818e062367, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 19 03:54:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960892, encodeId=4bc9196089273, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 02 06:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043722, encodeId=8c9c2043e22e6, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 17:54:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313841, encodeId=192a313841f6, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu May 10 15:02:37 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313808, encodeId=a4cd313808d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 10 12:58:52 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2019-02-03 xzw113
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059300, encodeId=e415205930097, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 03 18:54:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870623, encodeId=a8e818e062367, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 19 03:54:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960892, encodeId=4bc9196089273, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 02 06:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043722, encodeId=8c9c2043e22e6, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 17:54:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313841, encodeId=192a313841f6, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu May 10 15:02:37 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313808, encodeId=a4cd313808d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 10 12:58:52 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059300, encodeId=e415205930097, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 03 18:54:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870623, encodeId=a8e818e062367, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 19 03:54:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960892, encodeId=4bc9196089273, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 02 06:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043722, encodeId=8c9c2043e22e6, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 17:54:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313841, encodeId=192a313841f6, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu May 10 15:02:37 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313808, encodeId=a4cd313808d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 10 12:58:52 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-11-02 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059300, encodeId=e415205930097, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 03 18:54:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870623, encodeId=a8e818e062367, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 19 03:54:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960892, encodeId=4bc9196089273, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 02 06:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043722, encodeId=8c9c2043e22e6, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 17:54:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313841, encodeId=192a313841f6, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu May 10 15:02:37 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313808, encodeId=a4cd313808d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 10 12:58:52 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-07-31 xue8602
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059300, encodeId=e415205930097, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 03 18:54:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870623, encodeId=a8e818e062367, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 19 03:54:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960892, encodeId=4bc9196089273, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 02 06:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043722, encodeId=8c9c2043e22e6, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 17:54:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313841, encodeId=192a313841f6, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu May 10 15:02:37 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313808, encodeId=a4cd313808d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 10 12:58:52 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 明月清辉

    谢谢分享.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2059300, encodeId=e415205930097, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 03 18:54:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870623, encodeId=a8e818e062367, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 19 03:54:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960892, encodeId=4bc9196089273, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 02 06:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043722, encodeId=8c9c2043e22e6, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 17:54:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313841, encodeId=192a313841f6, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu May 10 15:02:37 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313808, encodeId=a4cd313808d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 10 12:58:52 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 虈亣靌

    学习了受益匪浅

    0

相关资讯

NEJM:多参数磁共振成像对前列腺的诊断的准确性优于标准活检

研究认为多参数磁共振成像对前列腺癌诊断的准确性优于标准活检

Clin Cancer Res:癌症干细胞和巨噬细胞互作能够促使前列腺癌恶化和增强雄激素阻断治疗抗性

癌症干细胞(CSCs)能够导致前列腺癌的恶化和雄激素阻断治疗(ADT)抗性的增强。由于CSCs依赖于它们特异的微环境,包括肿瘤相关的巨噬细胞(TAMs),阐释CSCs和TAMs之间的互作网络也许能够更加有效的抑制前列腺癌的恶化和对ADT的抗性。研究人员利用RNA-seq、co-IP和其他的试验评估了维持CSCs干细胞特性的细胞内机制,还利用共培养系统和细胞激素抗体试验来检测CSCs和TAMs之间的

Prostate Cancer P D:雄激素阻断治疗前列腺癌男性中的并发症研究

雄激素阻断治疗使用的增加促进了人们对其副作用进一步的评估,因为这种疗法也许能够加速或者增加发展新并发症疾病的风险。最近,有研究人员评估了澳大利亚前列腺癌男性接受雄激素阻断治疗后的并发症情况。研究发现,与对照组相比,研究中的前列腺癌群体具有发展为心血管疾病显著更高的风险(风险比:1.37, 95% CI: 1.26-1.48)、以及抑郁(1.86, 95% CI: 1.73-2.01)、糖尿病(1.

Nat Commun:前馈α粒子放射治疗能够根治雄激素受体依赖的前列腺癌

人类激肽释放酶肽酶2(hk2)是一种前列腺特异性酶,它的表达受雄激素受体(AR)控制。AR是前列腺癌(PCa)的核心致瘤驱使因子,并且在癌症的DNA修复过程是是关键的调控因子。最近,有研究人员报道了一个创新的治疗策略,该策略利用了激素-DNA修复回路来促使分子特异性的α粒子在PCa中的注入。前列腺癌α粒子注入是通过分子特异性靶标位点和针对hK2的人源化单克隆抗体hu11B6的内化来引起的,并且进一

Nat Commun:在前列腺癌中,Frizzled-8能够结合Wnt-11和转化生长因子-β信号

Wnt-11能够促进前列腺癌细胞的迁移和入侵,并且不依赖与β-连环蛋白,但是相关的参与的受体仍旧未知。最近,有研究人员在前列腺癌中,探明了FZD8是Wnt-11的主要受体,并且与Wnt-11和TGF-β信号结合来促进上皮-间质转化(EMT)。研究发现,在体内和体外中,FZD8 mRNA在多个前列腺癌数据集和多个转移性癌细胞系中表达上调。患者样本分析阐释了癌症中FZD8的水平增加,并且与Wnt-11

Nat Commun:多方面的免疫调控和组织向性临床细菌分离能够促进前列腺癌免疫治疗

免疫检查点抑制剂对一些免疫反应迟钝的肿瘤并不十分有效,比如前列腺癌,且前列腺癌还包括了罕见的肿瘤浸润淋巴细胞现象。最近,有研究人员假设选择组织特异性和免疫调控细菌能够促进这些免疫治疗的效果。研究人员在研究中展示了一个来源于病人的前列腺特异性细菌,CP1,结合抗PD-1免疫治疗方法,能够在正位的MYC-和PTEN突变的前列腺癌模型中增加生存且减少肿瘤负担。CP1在尿道内特异性定殖并且能够在肿瘤上增殖